Brief: Island Pharmaceuticals Announces Signing Of Clinical Trial Support Services Agreement, For Island's Upcoming Isla-101 Phase 2A Peach Study
04/01/2022 01:20
Jan 4 (Reuters) - Island Pharmaceuticals Ltd ILA.AX :
* ANNOUNCES SIGNING OF CLINICAL TRIAL SUPPORT SERVICES
AGREEMENT,
FOR ISLAND'S UPCOMING ISLA-101 PHASE 2A PEACH STUDY
Source text for Eikon: ID:nASX3F4vbl
Further company coverage: ILA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic